Inherent and Acquired Resistance to Paclitaxel in Hepatocellular Carcinoma: Molecular Events Involved

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Meena, Avtar Singh ^a   Sharma, Aanchal ^a,b   Kumari, Ratna ^a,c   Mohammad, Naoshad ^a   Singh, Shivendra Vikram ^a   Bhat, Manoj Kumar ^a  

^a NATIONAL CENTRE FOR CELL SCIENCE   (India)

^b Daiichi Sankyo India Pharma Pvt Ltd   (India)

^c KIIT UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CAVEOLIN 1; CERULENIN; CISPLATIN; CYTOCHROME P450; DOXORUBICIN; FATTY ACID SYNTHASE; METHOTREXATE; METHYL BETA CYCLODEXTRIN; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; SMALL INTERFERING RNA; VINBLASTINE;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL ASSAY; CELL CLONE; CELL SELECTION; CELL SURVIVAL; CELL TYPE; CONTROLLED STUDY; CROSS RESISTANCE; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME INHIBITION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; LONG TERM SURVIVAL; MOLECULAR INTERACTION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SINGLE CELL ANALYSIS;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, HEPATOCELLULAR; CAVEOLIN 1; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FATTY ACID SYNTHETASE COMPLEX; HUMANS; LIVER NEOPLASMS; METHOTREXATE; P-GLYCOPROTEIN; PACLITAXEL; VINBLASTINE;

EID: 84876183055     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061524     Document Type: Article

References (32)

1. Semela D, Heim M, (2011) Hepatocellular carcinoma. Ther Umsch 68(4): 213-217.
2. Wong R, Frenette C, (2011) Updates in the management of hepatocellular carcinoma. Gastroenterol Hepatol (N Y) 7(1): 16-24.
3. Lin DY, Lin SM, Liaw YF, (1997) Non-surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 12(9-10): S319-28.
4. Peetla C, Bhave R, Vijayaraghavalu S, Stine A, Kooijman E, et al. (2010) Drug resistance in breast cancer cells: biophysical characterization of and doxorubicin interactions with membrane lipids. Mol Pharm 7(6): 2334-48.
5. Seddon AM, Casey D, Law RV, Gee A, Templer RH, et al. (2009) Drug interactions with lipid membranes. Chem Soc ReV 38: 2509-2519.
6. Righetti SC, Perego P, Carenini N, Corna E, Dal Bo L, et al. (2006) Molecular alterations of cells resistant to platinum drugs: role of PKCalpha. Biochim Biophys Acta 1763(1): 93-100.
7. Dai Z, Huang Y, Sadée W, (2004) Growth factor signaling and resistance to cancer chemotherapy. Curr Top Med Chem 4(13): 1347-1356.
8. Gillet JP, Gottesman MM, (2010) Mechanisms of multidrug resistance in cancer. Methods Mol Biol 596: 47-76.
9. Henley D, Isbill M, Fernando R, Foster1 JS, Wimalasena J (2007) Paclitaxel induced apoptosis in breast cancer cells requires cell cycle transit but not Cdc2 activity. Cancer Chemother Pharmacol 59(2): 235-249.
10. Ofir R, Seidman R, Rabinski T, Krup M, Yavelsky V, et al. (2002) Taxol-induced apoptosis in human SKOV3 ovarian and MCF7 breast carcinoma cells is caspase-3 and caspase-9 independent. Cell Death Differ 9(6): 636-42.
11. Andrea F, Robert B, Robert KS, (1997) Abrogation of taxol induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids. Cancer Res 57(12): 2388-2393.
12. Selleri S, Arnaboldi F, Palazzo M, Hussein U, Balsari A, et al. (2005) Caveolin-1 is expressed on multipotent cells of hair follicles and might be involved in their resistance to chemotherapy. Br J Dermatol 153(3): 506-513.
13. Shajahan AN, Wang A, Decker M, Minshall RD, Liu MC, et al. (2007) Caveolin-1 tyrosine phosphorylation enhances paclitaxel-mediated cytotoxicity. J Biol Chem 282 (8): 5934-5943.
14. Tse EY, Ko FC, Tung EK, Chan LK, Lee TK, et al. (2012) Caveolin-1 overexpression is associated with hepatocellular carcinoma tumourigenesis and metastasis. J Pathol 226(4): 645-53.
15. Tang Y, Zeng X, He F, Liao Y, Qian N, et al. (2012) Caveolin-1 is related to invasion, survival, and poor prognosis in hepatocellular cancer. Med Oncol 29(2): 977-84.
16. Liu H, Liu Y, Zhang JT, (2008) A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproduction. Mol Cancer Ther 7(2): 263-270.
17. Pandey V, Vijayakumar MV, Ajay AK, Malvi P, Bhat MK, (2012) Diet-induced obesity increases melanoma progression: involvement of Cav-1 and FASN. Int J Cancer 130(3): 497-508.
18. Chhipa RR, Kumari R, Upadhyay AK, Bhat MK, (2007) Abrogation of p53 by its antisense in MCF-7 breast carcinoma cells increases cyclin D1 via activation of Akt and promotion of cell proliferation. Exp Cell Res 313(19): 3945-58.
19. Patel VA, Dunn MJ, Sorokin A, (2002) Regulation of MDR-1 (P-glycoprotein) by cyclooxyenase-2. J Biol Chem 277(41): 38915-20.
20. Thomas S, Overdevest JB, Nitz MD, Williams PD, Owens CR, et al. (2011) Src and Caveolin-1 reciprocally regulate metastasis via common downstream signaling pathways in bladder cancer. Cancer Res 71(3): 832-41.
21. Ogu CC, PharmD1 and Maxa JL (2000) Drug interactions due to CYP450. Proc (Bayl Univ Med Cent) 13(4): 421-423.
22. Landriscina M, Amoroso MR, Piscazzi A, Esposito F, (2010) Heat shock proteins, cell survival and drug resistance: the mitochondrial chaperone TRAP1, a potential novel target for ovarian cancer therapy. Gynecol Oncol 117(2): 177-182.
23. Sharma A, Meena AS, Bhat MK, (2010) Hyperthermia-associated carboplatin resistance: differential role of p53, HSF1 and Hsp70 in hepatoma cells. Cancer Sci 101(5): 1186-1193.
24. Cohen M, Dromard M, Petignat P, (2010) Heat shock proteins in ovarian cancer: a potential target for therapy. Gynecol Oncol 119(1): 164-166.
25. Hsu HS, Lin JH, Huang WC, Hsu TW, Su K, et al. (2011) Chemoresistance of lung cancer stemlike cells depends on activation of Hsp27. Cancer 117(7): 1516-28.
26. Mellor HR, Callaghan R, (2008) Resistance to chemotherapy in cancer: a complex and integrated cellular response. Pharmacology 81(4): 275-300.
27. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM, (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5(3): 219-234.
28. Germann UA, Chambers TC, (1998) Molecular analysis of the multidrug transporter, P-glycoprotein. Cytotechnology 27(1-3): 31-60.
29. Xu Y, Zhi F, Xu G, Tang X, Lu S, et al. (2012) Overcoming multidrug resistance in vitro and in vivo by a novel P-glycoprotein inhibitor 1416. Biosci Rep (Epub ahead of print).
30. Gillet JP, Calcagno AM, Varma S, Marino M, Green LJ, et al. (2011) Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A 108(46): 18708-13.
31. Hutchison DJ, (1965) Studies on cross-resistance and collateral sensitivity (1962-1964) Cancer Res. 25: 1581-1595.
32. Özlem DI, Meltem DK, Seçkin E, Ufuk G, (2009) Drug resistant MCF-7 cell lines also developed cross-resistance to structurally unrelated anticancer agents. International Journal of Hematology and Oncology 19(1): 001-008.